Pub Date : 2022-12-27DOI: 10.15406/jccr.2022.15.00567
Andrés Di Leoni Ferrari, E. Bartholomay, Fabio Michalsky Velho, A. Borges, Matheus Bom Fraga, Luis Manuel Ley Domingues, J. C. Pachón Mateos
{"title":"Atrioventricular dyssynchrony in patients with permanent pacemaker due to sinus node dysfunction and first-degree atrioventricular block: does the long PR syndrome exist?","authors":"Andrés Di Leoni Ferrari, E. Bartholomay, Fabio Michalsky Velho, A. Borges, Matheus Bom Fraga, Luis Manuel Ley Domingues, J. C. Pachón Mateos","doi":"10.15406/jccr.2022.15.00567","DOIUrl":"https://doi.org/10.15406/jccr.2022.15.00567","url":null,"abstract":"","PeriodicalId":115064,"journal":{"name":"Journal of Cardiology & Current Research","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121279105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-08-08DOI: 10.15406/jccr.2022.15.00562
L. K. Junior, Naiara Pedrassi Engracia Garcia Caluz, Anita L R Saldanha, A. L. Valera Gasparoto, Bruno de Carvalho Abdala, Paulo Maurício Garcia Nosé, Dalton Fonseca Almeida, Tereza Luiza Bellincanta Fakhouri, Ana Paula Pantoja Margeotto, Tania Leme da Rocha Martinez
In spite of the first trials on the effect of cholesterol reduction and its beneficial impact on morbidity and mortality in the elderly many have already proven the antecipated positive results. The high risk attributable to the elderly is a guarantee for an effort in primary prevention, especially when a high level of serum cholesterol is combined with other risk factors linked to coronary artery disease. There are elements of similarity for primary prevention in the elderly over 65 years of age, compared to middle-aged patients. This consideration opened the need for scientific evidence with confirmed levels of evidence. The first studies were WOSCOPS, AFCAPS/TEXCAPS, Heart Protection Study, PROSPER, ALLHAT (Antihipertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial-Lipid Lowering Trial), REVERSAL, Health Study, ASCOT (Anglo Scandinavian Cardiac Outcomes), MIRACL, Post CABG, AVERT, ACCESS, ASSET, ATGOAL, CHALLENGE, CURVES, BELLS, ARBITER, NASDAC, PROVE-IT and DEBATE. Positive evidences were shown from the first to the last trial recalled in this historical beginning.
{"title":"Hypolipidemic trials in the elderly - a recent historic standpoint","authors":"L. K. Junior, Naiara Pedrassi Engracia Garcia Caluz, Anita L R Saldanha, A. L. Valera Gasparoto, Bruno de Carvalho Abdala, Paulo Maurício Garcia Nosé, Dalton Fonseca Almeida, Tereza Luiza Bellincanta Fakhouri, Ana Paula Pantoja Margeotto, Tania Leme da Rocha Martinez","doi":"10.15406/jccr.2022.15.00562","DOIUrl":"https://doi.org/10.15406/jccr.2022.15.00562","url":null,"abstract":"In spite of the first trials on the effect of cholesterol reduction and its beneficial impact on morbidity and mortality in the elderly many have already proven the antecipated positive results. The high risk attributable to the elderly is a guarantee for an effort in primary prevention, especially when a high level of serum cholesterol is combined with other risk factors linked to coronary artery disease. There are elements of similarity for primary prevention in the elderly over 65 years of age, compared to middle-aged patients. This consideration opened the need for scientific evidence with confirmed levels of evidence. The first studies were WOSCOPS, AFCAPS/TEXCAPS, Heart Protection Study, PROSPER, ALLHAT (Antihipertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial-Lipid Lowering Trial), REVERSAL, Health Study, ASCOT (Anglo Scandinavian Cardiac Outcomes), MIRACL, Post CABG, AVERT, ACCESS, ASSET, ATGOAL, CHALLENGE, CURVES, BELLS, ARBITER, NASDAC, PROVE-IT and DEBATE. Positive evidences were shown from the first to the last trial recalled in this historical beginning.","PeriodicalId":115064,"journal":{"name":"Journal of Cardiology & Current Research","volume":"102 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126972124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-08-08DOI: 10.15406/jccr.2022.15.00563
C. Barrera-Ramı́rez, L. Pineda-Pompa, María del Rayo Pacheco Ríos, H. Ilárraza-Lomelí
Background: Recent evidence demonstrates that morphine significantly reduces absorption and delays onset of action of P2Y12-receptor inhibitors in patients with acute coronary syndrome. Case summary: 55-year-old male with inferior ST-segment–elevation myocardial infarction was treated with opioids previous and during primary angioplasty, developing temporary and reversible clopidogrel, ticagrelor and prasugrel high on-treatment platelet reactivity assessed by platelet function test. We treated with glycoprotein IIb/IIIa inhibitor as a bridge to obtain antplatelet effect by P2Y12–receptor inhibitors. Discussion: The interaction between opioids and oral P2Y12-receptor inhibitors in patients with acute coronary syndrome should be highlighted. Although morphine administration may potentially lead to detrimental clinical consequences by diminish of antiplatelet effect, its routine avoidance cannot be recommended until large scale trials be available. We suggest that if the use of morphine and other opioids is inevitable, utilization of platelet function tests to guide the antiplatelet treatment is an option.
{"title":"Temporary and reversible clopidogrel, ticagrelor and prasugrel high on-treatment platelet reactivity associated to the concomitant use of morphine and fentanyl in acute coronary syndrome","authors":"C. Barrera-Ramı́rez, L. Pineda-Pompa, María del Rayo Pacheco Ríos, H. Ilárraza-Lomelí","doi":"10.15406/jccr.2022.15.00563","DOIUrl":"https://doi.org/10.15406/jccr.2022.15.00563","url":null,"abstract":"Background: Recent evidence demonstrates that morphine significantly reduces absorption and delays onset of action of P2Y12-receptor inhibitors in patients with acute coronary syndrome. Case summary: 55-year-old male with inferior ST-segment–elevation myocardial infarction was treated with opioids previous and during primary angioplasty, developing temporary and reversible clopidogrel, ticagrelor and prasugrel high on-treatment platelet reactivity assessed by platelet function test. We treated with glycoprotein IIb/IIIa inhibitor as a bridge to obtain antplatelet effect by P2Y12–receptor inhibitors. Discussion: The interaction between opioids and oral P2Y12-receptor inhibitors in patients with acute coronary syndrome should be highlighted. Although morphine administration may potentially lead to detrimental clinical consequences by diminish of antiplatelet effect, its routine avoidance cannot be recommended until large scale trials be available. We suggest that if the use of morphine and other opioids is inevitable, utilization of platelet function tests to guide the antiplatelet treatment is an option.","PeriodicalId":115064,"journal":{"name":"Journal of Cardiology & Current Research","volume":"29 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127277841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-21DOI: 10.15406/jccr.2022.15.00561
Belal Sultanzai, E. Amsterdam
{"title":"Up is down, down is up: ectopic atrial bradycardia or junctional Rhythm?","authors":"Belal Sultanzai, E. Amsterdam","doi":"10.15406/jccr.2022.15.00561","DOIUrl":"https://doi.org/10.15406/jccr.2022.15.00561","url":null,"abstract":"","PeriodicalId":115064,"journal":{"name":"Journal of Cardiology & Current Research","volume":"258 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122712425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-30DOI: 10.15406/jccr.2022.15.00559
V. Lukyanov, Purvee Parikh, Heather Luke, Jennifer Lavelle, G. Medic, Andrew Armanious, Leigh Ann Kelly, Manish Wadhwa MD, Marie Noelle-Langan MD
{"title":"Outpatient cardiac telemetry monitoring for early patient discharge: continuous focused rhythm surveillance for patients recovering outside of the hospital setting","authors":"V. Lukyanov, Purvee Parikh, Heather Luke, Jennifer Lavelle, G. Medic, Andrew Armanious, Leigh Ann Kelly, Manish Wadhwa MD, Marie Noelle-Langan MD","doi":"10.15406/jccr.2022.15.00559","DOIUrl":"https://doi.org/10.15406/jccr.2022.15.00559","url":null,"abstract":"","PeriodicalId":115064,"journal":{"name":"Journal of Cardiology & Current Research","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129147969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-14DOI: 10.15406/jccr.2022.15.00552
A. Leone
{"title":"A panoramic view of the myocardial infarction. etiology, pathology, and comparison with the past","authors":"A. Leone","doi":"10.15406/jccr.2022.15.00552","DOIUrl":"https://doi.org/10.15406/jccr.2022.15.00552","url":null,"abstract":"","PeriodicalId":115064,"journal":{"name":"Journal of Cardiology & Current Research","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133643338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-11DOI: 10.15406/jccr.2022.15.00551
Anuradha Ghosal, S. Ghosal
Type 2 diabetes mellitus (T2DM) is the most frequent metabolic disease encountered in India. One of the most fearful complications associated with T2DM is acute coronary syndrome (ACS). In contrast to the non-T2DM patients T2DM patients presents with atypical clinical picture and has a worse prognosis. Electrocardiogram (ECG) is a very important tool used to diagnose ACS. The ST-segment elevation (STEMI) pattern in ECG is associated with a significant and prolonged occlusion of the coronary arteries. The aim of this pilot project was to highlight the difference in ECG presentation between T2DM patients and their non-T2DM counterparts (if any). Relevant data was collected from 29 consecutive patients presenting with AMI in the cardiac care center in Nightingale hospital, Kolkata, India, after procuring their informed consent. The data was analyzed using the presence or absence of STEMI as the categorical output and its association with T2DM status as the input. The association was assessed using chi-square statistics. Jupyter notebook was used to perform the statistical analysis. The mean age of the selected population was 61.2 years with a mean blood pressure (BP) of 136/77 mm of Hg. There was a significant association between T2DM and STEMI (P=0.02), as assessed by chi-square statistics. In this small cohort from Kolkata, T2DM was significantly associated with an ECG presentation of STEMI in patients with AMI.
2型糖尿病(T2DM)是印度最常见的代谢疾病。与T2DM相关的最可怕的并发症之一是急性冠脉综合征(ACS)。与非T2DM患者相比，T2DM患者临床表现不典型，预后较差。心电图(ECG)是诊断ACS的重要工具。心电图st段抬高(STEMI)模式与冠状动脉明显和长期闭塞有关。这个试点项目的目的是强调T2DM患者和非T2DM患者(如果有的话)之间心电图表现的差异。在获得知情同意后，从印度加尔各答南丁格尔医院心脏护理中心连续29例AMI患者中收集相关数据。将STEMI是否存在作为分类输出，并将其与T2DM状态的关联作为输入，对数据进行分析。使用卡方统计来评估相关性。采用Jupyter笔记本进行统计分析。所选人群的平均年龄为61.2岁，平均血压(BP)为136/77 mm Hg。经卡方统计，T2DM与STEMI之间存在显著相关性(P=0.02)。在这个来自加尔各答的小队列中，T2DM与AMI患者的STEMI的心电图表现显著相关。
{"title":"Frequency of ST-segment elevation acute myocardial infarction in patients with Type 2 Diabetes Mellitus","authors":"Anuradha Ghosal, S. Ghosal","doi":"10.15406/jccr.2022.15.00551","DOIUrl":"https://doi.org/10.15406/jccr.2022.15.00551","url":null,"abstract":"Type 2 diabetes mellitus (T2DM) is the most frequent metabolic disease encountered in India. One of the most fearful complications associated with T2DM is acute coronary syndrome (ACS). In contrast to the non-T2DM patients T2DM patients presents with atypical clinical picture and has a worse prognosis. Electrocardiogram (ECG) is a very important tool used to diagnose ACS. The ST-segment elevation (STEMI) pattern in ECG is associated with a significant and prolonged occlusion of the coronary arteries. The aim of this pilot project was to highlight the difference in ECG presentation between T2DM patients and their non-T2DM counterparts (if any). Relevant data was collected from 29 consecutive patients presenting with AMI in the cardiac care center in Nightingale hospital, Kolkata, India, after procuring their informed consent. The data was analyzed using the presence or absence of STEMI as the categorical output and its association with T2DM status as the input. The association was assessed using chi-square statistics. Jupyter notebook was used to perform the statistical analysis. The mean age of the selected population was 61.2 years with a mean blood pressure (BP) of 136/77 mm of Hg. There was a significant association between T2DM and STEMI (P=0.02), as assessed by chi-square statistics. In this small cohort from Kolkata, T2DM was significantly associated with an ECG presentation of STEMI in patients with AMI.","PeriodicalId":115064,"journal":{"name":"Journal of Cardiology & Current Research","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129873086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-07DOI: 10.15406/jccr.2022.15.00550
T. Shibata, Eiko Fukuro, Hirotake Takahashi, Y. Kayama, C. Mori, M. Kawai, M. Yoshimura
Objective: The purpose of this study is to investigate the factors that influence the effectiveness of tolvaptan treatment for acute decompensated heart failure. Methods and patients: This retrospective study included 102 patients with acute decompensated heart failure who were considered to require tolvaptan. We investigated whether tolvaptan administration was completed within 7 days or more and divided patients into two groups accordingly (responders, n = 35, non-responders, n = 67). Univariate, multivariate analysis and structural equation modeling were used to investigate the various clinical features involved in the success or failure of tolvaptan administration within 7 days. Among the investigation of various factors, changes in blood urea nitrogen, creatinine, and hemoglobin before and after tolvaptan administration were associated with the completion of tolvaptan administration. In order to proceed with further examination, we examined using a path diagram based on structural equation modeling. Results: It was found that low hemoglobin before treatment and high hemoglobin after treatment are related to the success of the completion of tolvaptan. Other factors were not related to the success of tolvaptan administration. The effectiveness of tolvaptan in pretreatment patients with low hemoglobin is especially important and hemoglobin level will be a valuable marker. Conclusion: This study showed that tolvaptan may be more effective at low hemoglobin in acute decompensated heart failure, which is generally difficult to treat. In that case, active use of tolvaptan is recommended.
{"title":"Relationship between the efficacy of tolvaptan and hemoglobin levels in acute decompensated heart failure","authors":"T. Shibata, Eiko Fukuro, Hirotake Takahashi, Y. Kayama, C. Mori, M. Kawai, M. Yoshimura","doi":"10.15406/jccr.2022.15.00550","DOIUrl":"https://doi.org/10.15406/jccr.2022.15.00550","url":null,"abstract":"Objective: The purpose of this study is to investigate the factors that influence the effectiveness of tolvaptan treatment for acute decompensated heart failure. Methods and patients: This retrospective study included 102 patients with acute decompensated heart failure who were considered to require tolvaptan. We investigated whether tolvaptan administration was completed within 7 days or more and divided patients into two groups accordingly (responders, n = 35, non-responders, n = 67). Univariate, multivariate analysis and structural equation modeling were used to investigate the various clinical features involved in the success or failure of tolvaptan administration within 7 days. Among the investigation of various factors, changes in blood urea nitrogen, creatinine, and hemoglobin before and after tolvaptan administration were associated with the completion of tolvaptan administration. In order to proceed with further examination, we examined using a path diagram based on structural equation modeling. Results: It was found that low hemoglobin before treatment and high hemoglobin after treatment are related to the success of the completion of tolvaptan. Other factors were not related to the success of tolvaptan administration. The effectiveness of tolvaptan in pretreatment patients with low hemoglobin is especially important and hemoglobin level will be a valuable marker. Conclusion: This study showed that tolvaptan may be more effective at low hemoglobin in acute decompensated heart failure, which is generally difficult to treat. In that case, active use of tolvaptan is recommended.","PeriodicalId":115064,"journal":{"name":"Journal of Cardiology & Current Research","volume":"43 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116494833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-28DOI: 10.15406/jccr.2022.15.00549
Christina Paitazoglou, M. Bergmann, D. Losik, E. Pokushalov, Vitaly A. Shabanov, A. Romanov
Objectives: Erythropoietin (EPO) improved cardiac regeneration in experimental models of ischemic heart disease. A pilot trial found subcutaneously administered EPO to improve surrogate markers of left ventricular (LV) function in ischemic cardiomyopathy. This clinical study tests the feasibility and safety of the intramyocardial delivery route of a long-acting EPO-analogue (C.E.R.A.) in patients with ischemic cardiomyopathy. Methods: The ALSTER C.E.R.A. trial was a Phase II, open label, 1:1 randomized, single-center study testing intramyocardial injections of long-acting EPO analogue C.E.R.A. (C.E.R.A. NOGA: once 180 µg) using the NOGA XP system versus the subcutaneous application (C.E.R.A. SC: 30µg s.c./month for 6 months) in 59 symptomatic chronic heart failure (HF) patients with impaired LV function (ejection fraction (EF) £ 45%). Results: Follow-up up to three years with both clinical and imaging endpoints found intramyocardial delivery of C.E.R.A. to be feasible, safe and to possibly attenuate LV remodeling. Patients in the C.E.R.A. NOGA group showed stable parameter for LV end-diastolic diameter and volume (LVEDD and LVEDV), while C.E.R.A. SC patients had significant dilation of the LV (C.E.R.A. NOGA vs. SC, mean ± standard error of the mean: DLVEDD 0.02±0.1mm, p=0.8 vs. 0.3±0.09mm, p=0.0026; DLVEDV 10±15.9ml, p=0.5 vs. 34.8±11.3ml, p=0.0081; ∆EF 2.4±1.2%, p=0.045 vs. -1.6±1.1, p=0.1 respectively). NYHA class significantly improved and the hospitalization rate was numerically reduced in the C.E.R.A. NOGA group, while three-year mortality was identical. Conclusions: Intramyocardial injection of C.E.R.A. is feasible, safe and possibly attenuates LV remodeling in ischemic HF patients with LV dysfunction compared to the systemic application.
目的:促红细胞生成素(EPO)促进缺血性心脏病实验模型的心脏再生。一项试点试验发现皮下注射EPO可改善缺血性心肌病左心室(LV)功能的替代标志物。本临床研究检验了一种长效epo -类似物(c.e.r.a)在缺血性心肌病患者心内递送途径的可行性和安全性。方法:ALSTER C.E.R.A.试验是一项II期、开放标签、1:1随机、单中心研究，使用NOGA XP系统对59例左室功能受损(射血分数为45%)的症状性慢性心力衰竭(HF)患者进行心肌内注射长效EPO类似物C.E.R.A. (C.E.R.A. NOGA:一次180µg)与皮下注射(C.E.R.A. SC: 30µg s.c./月，持续6个月)。结果:经过长达三年的临床和影像学随访，发现心内灌注C.E.R.A.是可行的、安全的，并可能减轻左室重构。C.E.R.A. NOGA组患者左室舒张末期直径和容积参数稳定(LVEDD和LVEDV)，而C.E.R.A. SC组患者左室明显扩张(C.E.R.A. NOGA vs. SC，平均±标准误差均值:DLVEDD 0.02±0.1mm, p=0.8 vs. 0.3±0.09mm, p=0.0026;DLVEDV 10±15.9ml, p=0.5 vs. 34.8±11.3ml, p=0.0081;∆EF 2.4±1.2%,p = 0.045和-1.6±1.1,p = 0.1)。ce.r.a. NOGA组NYHA分级显著提高，住院率显著降低，三年死亡率相同。结论:与全身应用相比，心内注射c.e.r.a对合并左室功能障碍的缺血性心衰患者是可行、安全且可能减轻左室重构的。
{"title":"Intramyocardial injections of erythropoietin-analogue C.E.R.A. in ischemic cardiomyopathy: the ALSTER C.E.R.A. trial","authors":"Christina Paitazoglou, M. Bergmann, D. Losik, E. Pokushalov, Vitaly A. Shabanov, A. Romanov","doi":"10.15406/jccr.2022.15.00549","DOIUrl":"https://doi.org/10.15406/jccr.2022.15.00549","url":null,"abstract":"Objectives: Erythropoietin (EPO) improved cardiac regeneration in experimental models of ischemic heart disease. A pilot trial found subcutaneously administered EPO to improve surrogate markers of left ventricular (LV) function in ischemic cardiomyopathy. This clinical study tests the feasibility and safety of the intramyocardial delivery route of a long-acting EPO-analogue (C.E.R.A.) in patients with ischemic cardiomyopathy. Methods: The ALSTER C.E.R.A. trial was a Phase II, open label, 1:1 randomized, single-center study testing intramyocardial injections of long-acting EPO analogue C.E.R.A. (C.E.R.A. NOGA: once 180 µg) using the NOGA XP system versus the subcutaneous application (C.E.R.A. SC: 30µg s.c./month for 6 months) in 59 symptomatic chronic heart failure (HF) patients with impaired LV function (ejection fraction (EF) £ 45%). Results: Follow-up up to three years with both clinical and imaging endpoints found intramyocardial delivery of C.E.R.A. to be feasible, safe and to possibly attenuate LV remodeling. Patients in the C.E.R.A. NOGA group showed stable parameter for LV end-diastolic diameter and volume (LVEDD and LVEDV), while C.E.R.A. SC patients had significant dilation of the LV (C.E.R.A. NOGA vs. SC, mean ± standard error of the mean: DLVEDD 0.02±0.1mm, p=0.8 vs. 0.3±0.09mm, p=0.0026; DLVEDV 10±15.9ml, p=0.5 vs. 34.8±11.3ml, p=0.0081; ∆EF 2.4±1.2%, p=0.045 vs. -1.6±1.1, p=0.1 respectively). NYHA class significantly improved and the hospitalization rate was numerically reduced in the C.E.R.A. NOGA group, while three-year mortality was identical. Conclusions: Intramyocardial injection of C.E.R.A. is feasible, safe and possibly attenuates LV remodeling in ischemic HF patients with LV dysfunction compared to the systemic application.","PeriodicalId":115064,"journal":{"name":"Journal of Cardiology & Current Research","volume":"12 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127648619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-11DOI: 10.15406/jccr.2022.15.00547
P. Gupta, D. Cieslak
{"title":"Diabetes: prevalence, causes, effects, physiology and risk of cardiovascular diseases","authors":"P. Gupta, D. Cieslak","doi":"10.15406/jccr.2022.15.00547","DOIUrl":"https://doi.org/10.15406/jccr.2022.15.00547","url":null,"abstract":"","PeriodicalId":115064,"journal":{"name":"Journal of Cardiology & Current Research","volume":"394 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122182916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：